PARAGANGLIOMA
Clinical trials for PARAGANGLIOMA explained in plain language.
Never miss a new study
Get alerted when new PARAGANGLIOMA trials appear
Sign up with your email to follow new studies for PARAGANGLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for slowing rare adrenal tumors
Disease control OngoingThis study is testing whether monthly injections of a drug called lanreotide can help control advanced or metastatic pheochromocytoma and paraganglioma—rare tumors that form in nerve tissue. It will enroll about 10 adults to see if the treatment safely slows tumor growth compared…
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: Antonio Fojo • Aim: Disease control
Last updated Apr 03, 2026 22:41 UTC
-
New drug duo targets Hard-to-Treat rare cancers
Disease control OngoingThis study is testing whether a combination of two oral drugs, talazoparib and temozolomide, can shrink advanced rare cancers that have spread and for which standard treatments have stopped working. The trial aims to see if this drug pair can stop tumor growth by damaging cancer …
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Targeted radiation therapy tested in teens with rare cancers
Disease control OngoingThis study is testing the safety and measuring the radiation dose of a drug called Lutathera in teenagers (ages 12 to 18) with specific rare tumors. Lutathera is a targeted radiation therapy that seeks out and delivers radiation to tumor cells. The main goals are to see how much …
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug tested for rare, aggressive adrenal tumors
Disease control OngoingThis study is testing whether the drug axitinib can shrink or slow the growth of rare adrenal gland tumors called pheochromocytoma and paraganglioma that have spread or returned after treatment. It involves 6 adult participants with confirmed, measurable disease. The main goal is…
Matched conditions: PARAGANGLIOMA
Phase: PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC